EUVIMEDObjevte EUVIMED
KommentarOpen access

Betatrophin

Jonas Ahnfelt-Rønne, Ole D Madsen

Islets · 2014-03 · 6 (2) · e28686

DOI: 10.4161/isl.28686 ↗

At a glance

Kommentar in Islets, published online on 2014-05-05. Written by Jonas Ahnfelt-Rønne and 1 co-authors. Institution: a Diabetes Research Unit; Novo Nordisk A/S; Måløv, Denmark. Major MEDLINE topics: Cell Proliferation. Cited 9 times so far (Crossref); 23 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Regenerative therapy in diabetes with the capacity to reconstitute a functional β-cell mass sufficient for glycemic control holds the promise to effectively prevent the development of devastating late complications due to the unique ability of the β-cell to sense and regulate blood-glucose levels. An ability that cannot be mimicked by insulin replacement therapy or any other means of current treatment regiments for very large patient populations. Recently, Douglas A. Melton's group from Harvard University reported the identification of a circulating protein secreted from the liver under insulin resistant states which is sufficient to dramatically and specifically increase the replication rate of β-cells in the mouse resulting in an increased functional β-cell mass over time. They re-named the factor betatrophin and described a number of exciting features of this molecule which suggested that it could be a potential candidate for development as a regenerative medicine in diabetes. The official name of the gene encoding mouse betatrophin is Gm6484, but it has been annotated a number of times under different names: EG624219, RIFL, Lipasin and ANGPTL8. The official human gene name is C19orf80, but it has also been annotated as TD26, LOC55908, as well as RIFL, Lipasin, ANGPTL8 and betatrophin.

Subjects

MeSH terms (MEDLINE)

Cell ProliferationAnimalsFemaleHumansInsulin-Secreting CellsMalePancreasPeptide Hormones

Author keywords

AGNPTL8LipasinRIFLbetatrophindiabetes

Substances

Peptide Hormones

Authors and institutions

  • a Diabetes Research Unit; Novo Nordisk A/S; Måløv, Denmark.

Cite

APA

Ahnfelt-Rønne, J., & Madsen, O. D. (2014). Betatrophin. Islets, 6(2), e28686. https://doi.org/10.4161/isl.28686

Vancouver

Ahnfelt-Rønne J, Madsen OD. Betatrophin. Islets. 2014;6(2):e28686. doi:10.4161/isl.28686

BibTeX
@article{AhnfeltRnne2014,
  author = {Ahnfelt-Rønne, Jonas and Madsen, Ole D},
  title = {Betatrophin},
  journal = {Islets},
  year = {2014},
  volume = {6},
  number = {2},
  pages = {e28686},
  doi = {10.4161/isl.28686}
}
Start for free →